{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:51:49Z","timestamp":1794009109078,"version":"4.8.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000043","name":"American Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"EIF | Stand Up To Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005979","name":"Lustgarten Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005979","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-026-01165-8","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T09:02:22Z","timestamp":1779699742000},"page":"928-943","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5745-2994","authenticated-orcid":false,"given":"Kimberly J.","family":"Perez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1046-4899","authenticated-orcid":false,"given":"Andressa","family":"Dias Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9157-5392","authenticated-orcid":false,"given":"Thomas B.","family":"Karasic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4427-986X","authenticated-orcid":false,"given":"Dalia","family":"Elganainy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suryun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan Y.","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3680-7642","authenticated-orcid":false,"given":"Runzi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Chul","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2497-9439","authenticated-orcid":false,"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1276-186X","authenticated-orcid":false,"given":"Simona","family":"Cristea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6010-9970","authenticated-orcid":false,"given":"Emma","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Truitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Gyu","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6725-1910","authenticated-orcid":false,"given":"Hui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Sloane","family":"Furniss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Brais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5655-0762","authenticated-orcid":false,"given":"Josh","family":"Remland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilena","family":"Gocheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4860-3033","authenticated-orcid":false,"given":"Jennifer S.","family":"Thalappillil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Cleary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Enzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9012-6982","authenticated-orcid":false,"given":"Marios","family":"Giannakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0631-1494","authenticated-orcid":false,"given":"Kimmie","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5337-5231","authenticated-orcid":false,"given":"Douglas A.","family":"Rubinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1529-3278","authenticated-orcid":false,"given":"Benjamin","family":"Schlechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Surana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6295-2013","authenticated-orcid":false,"given":"Harshabad","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursina","family":"Teitelbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natallia","family":"Izgur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-4444","authenticated-orcid":false,"given":"Eliezer","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5374-9918","authenticated-orcid":false,"given":"Srivatsan","family":"Raghavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen Jen","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4723-7681","authenticated-orcid":false,"given":"Daniel","family":"Von Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Liddle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Downes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9986-5965","authenticated-orcid":false,"given":"Ronald M.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9302-4073","authenticated-orcid":false,"given":"Peter","family":"O\u2019Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0701-6203","authenticated-orcid":false,"given":"Andrew","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0943-7407","authenticated-orcid":false,"given":"Jonathan A.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0455-1032","authenticated-orcid":false,"given":"Brian M.","family":"Wolpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"1165_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park, W., Chawla, A. & O\u2019Reilly, E. M. Pancreatic Cancer: A Review. JAMA 326, 851\u2013862 (2021).","journal-title":"JAMA"},{"key":"1165_CR2","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691\u20131703 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1165_CR3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817\u20131825 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1165_CR4","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg, Z. A. et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 402, 1272\u20131281 (2023).","journal-title":"Lancet"},{"key":"1165_CR5","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2159-8290.CD-24-0002","volume":"14","author":"J Prakash","year":"2024","unstructured":"Prakash, J. & Shaked, Y. The Interplay between Extracellular Matrix Remodeling and Cancer Therapeutics. Cancer Discov. 14, 1375\u20131388 (2024).","journal-title":"Cancer Discov."},{"key":"1165_CR6","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ccell.2023.02.015","volume":"41","author":"G Caligiuri","year":"2023","unstructured":"Caligiuri, G. & Tuveson, D. A. Activated fibroblasts in cancer: Perspectives and challenges. Cancer Cell 41, 434\u2013449 (2023).","journal-title":"Cancer Cell"},{"key":"1165_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","volume":"18","author":"MH Sherman","year":"2023","unstructured":"Sherman, M. H. & Beatty, G. L. Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance. Annu. Rev. Pathol. 18, 123\u2013148 (2023).","journal-title":"Annu. Rev. Pathol."},{"key":"1165_CR8","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1158\/2159-8290.CD-20-0841","volume":"11","author":"SM Liudahl","year":"2021","unstructured":"Liudahl, S. M. et al. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Cancer Discov. 11, 2014\u20132031 (2021).","journal-title":"Cancer Discov."},{"key":"1165_CR9","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.1158\/1078-0432.CCR-22-1125","volume":"28","author":"A Dias Costa","year":"2022","unstructured":"Dias Costa, A. et al. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Clin. Cancer Res. 28, 5167\u20135179 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1165_CR10","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1016\/j.cell.2021.09.022","volume":"184","author":"BT Gr\u00fcnwald","year":"2021","unstructured":"Gr\u00fcnwald, B. T. et al. Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell 184, 5577\u20135592 (2021).","journal-title":"Cell"},{"key":"1165_CR11","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1158\/0008-5472.CAN-23-2352","volume":"84","author":"JH Sussman","year":"2024","unstructured":"Sussman, J. H. et al. Multiplexed Imaging Mass Cytometry Analysis Characterizes the Vascular Niche in Pancreatic Cancer. Cancer Res. 84, 2364\u20132376 (2024).","journal-title":"Cancer Res."},{"key":"1165_CR12","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1126\/science.1171362","volume":"324","author":"KP Olive","year":"2009","unstructured":"Olive, K. P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457\u20131461 (2009).","journal-title":"Science"},{"key":"1165_CR13","doi-asserted-by":"crossref","unstructured":"Provenzano, P. P. et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21, 418\u2013429 (2012).","DOI":"10.1016\/j.ccr.2012.01.007"},{"key":"1165_CR14","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig, C. et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl Acad. Sci. USA 110, 20212\u201320217 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1165_CR15","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","volume":"25","author":"AD Rhim","year":"2014","unstructured":"Rhim, A. D. et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25, 735\u2013747 (2014).","journal-title":"Cancer Cell"},{"key":"1165_CR16","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC \u00d6zdemir","year":"2014","unstructured":"\u00d6zdemir, B. C. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719\u2013734 (2014).","journal-title":"Cancer Cell"},{"key":"1165_CR17","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ccell.2021.02.007","volume":"39","author":"Y Chen","year":"2021","unstructured":"Chen, Y. et al. Type I collagen deletion in \u03b1SMA(+) myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. Cancer Cell 39, 548\u2013565 (2021).","journal-title":"Cancer Cell"},{"key":"1165_CR18","doi-asserted-by":"publisher","unstructured":"Bhattacharjee, S. et al. Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. J. Clin. Invest. https:\/\/doi.org\/10.1172\/jci146987 (2021).","DOI":"10.1172\/jci146987"},{"key":"1165_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s13105-022-00941-1","volume":"79","author":"X Liu","year":"2023","unstructured":"Liu, X., Iovanna, J. & Santofimia-Casta\u00f1o, P. Stroma-targeting strategies in pancreatic cancer: a double-edged sword. J. Physiol. Biochem. 79, 213\u2013222 (2023).","journal-title":"J. Physiol. Biochem."},{"key":"1165_CR20","doi-asserted-by":"publisher","first-page":"189065","DOI":"10.1016\/j.bbcan.2023.189065","volume":"1879","author":"M Chakkera","year":"2024","unstructured":"Chakkera, M., Foote, J. B., Farran, B. & Nagaraju, G. P. Breaking the stromal barrier in pancreatic cancer: advances and challenges. Biochim. Biophys. Acta Rev. Cancer 1879, 189065 (2024).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"1165_CR21","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada, E. et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 9, 1102\u20131123 (2019).","journal-title":"Cancer Discov."},{"key":"1165_CR22","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1158\/2159-8290.CD-23-0013","volume":"13","author":"ES Carpenter","year":"2023","unstructured":"Carpenter, E. S. et al. Analysis of donor pancreata defines the transcriptomic signature and microenvironment of early neoplastic lesions. Cancer Discov. 13, 1324\u20131345 (2023).","journal-title":"Cancer Discov."},{"key":"1165_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2024.07.001","author":"ATF Bell","year":"2024","unstructured":"Bell, A. T. F. et al. PanIN and CAF transitions in pancreatic carcinogenesis revealed with spatial data integration. Cell Syst. https:\/\/doi.org\/10.1016\/j.cels.2024.07.001 (2024).","journal-title":"Cell Syst."},{"key":"1165_CR24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cell.2014.08.007","volume":"159","author":"MH Sherman","year":"2014","unstructured":"Sherman, M. H. et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159, 80\u201393 (2014).","journal-title":"Cell"},{"key":"1165_CR25","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s43018-022-00349-2","volume":"3","author":"AN Hosein","year":"2022","unstructured":"Hosein, A. N., Dougan, S. K., Aguirre, A. J. & Maitra, A. Translational advances in pancreatic ductal adenocarcinoma therapy. Nat. Cancer 3, 272\u2013286 (2022).","journal-title":"Nat. Cancer"},{"key":"1165_CR26","doi-asserted-by":"publisher","first-page":"105557","DOI":"10.1016\/j.jsbmb.2019.105557","volume":"198","author":"JC Fleet","year":"2020","unstructured":"Fleet, J. C., Burcham, G. N., Calvert, R. D., Elzey, B. D. & Ratliff, T. L. 1\u03b1, 25 Dihydroxyvitamin D (1,25(OH)(2)D) inhibits the T cell suppressive function of myeloid derived suppressor cells (MDSC). J. Steroid Biochem. Mol. Biol. 198, 105557 (2020).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"1165_CR27","doi-asserted-by":"publisher","first-page":"113553","DOI":"10.1016\/j.biopha.2022.113553","volume":"154","author":"H Kim","year":"2022","unstructured":"Kim, H. et al. Calcipotriol, a synthetic vitamin D analog, promotes antitumor immunity via CD4+T-dependent CTL\/NK cell activation. Biomed. Pharmacother. 154, 113553 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"1165_CR28","doi-asserted-by":"publisher","unstructured":"Li, P. et al. 1\u03b1,25(OH)(2)D(3) reverses exhaustion and enhances antitumor immunity of human cytotoxic T cells. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2021-003477 (2022).","DOI":"10.1136\/jitc-2021-003477"},{"key":"1165_CR29","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1126\/science.adh7954","volume":"384","author":"E Giampazolias","year":"2024","unstructured":"Giampazolias, E. et al. Vitamin D regulates microbiome-dependent cancer immunity. Science 384, 428\u2013437 (2024).","journal-title":"Science"},{"key":"1165_CR30","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nm.2344","volume":"17","author":"EA Collisson","year":"2011","unstructured":"Collisson, E. A. et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17, 500\u2013503 (2011).","journal-title":"Nat. Med."},{"key":"1165_CR31","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt, R. A. et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet. 47, 1168\u20131178 (2015).","journal-title":"Nat. Genet."},{"key":"1165_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47\u201352 (2016).","journal-title":"Nature"},{"key":"1165_CR33","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1016\/j.cell.2021.11.017","volume":"184","author":"S Raghavan","year":"2021","unstructured":"Raghavan, S. et al. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell 184, 6119\u20136137 (2021).","journal-title":"Cell"},{"key":"1165_CR34","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1158\/0008-5472.CAN-22-3050","volume":"83","author":"HL Williams","year":"2023","unstructured":"Williams, H. L. et al. Spatially resolved single-cell assessment of pancreatic cancer expression subtypes reveals co-expressor phenotypes and extensive intratumoral heterogeneity. Cancer Res. 83, 441\u2013455 (2023).","journal-title":"Cancer Res."},{"key":"1165_CR35","doi-asserted-by":"publisher","first-page":"26835","DOI":"10.1073\/pnas.1914915116","volume":"116","author":"RL Porter","year":"2019","unstructured":"Porter, R. L. et al. Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Proc. Natl Acad. Sci. USA 116, 26835\u201326845 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1165_CR36","doi-asserted-by":"publisher","first-page":"e0233705","DOI":"10.1371\/journal.pone.0233705","volume":"15","author":"X Geng","year":"2020","unstructured":"Geng, X., Shi, E., Wang, S. & Song, Y. A comparative analysis of the efficacy and safety of paricalcitol versus other vitamin D receptor activators in patients undergoing hemodialysis: a systematic review and meta-analysis of 15 randomized controlled trials. PLoS ONE 15, e0233705 (2020).","journal-title":"PLoS ONE"},{"key":"1165_CR37","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1126\/science.1195300","volume":"330","author":"M Kraman","year":"2010","unstructured":"Kraman, M. et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330, 827\u2013830 (2010).","journal-title":"Science"},{"key":"1165_CR38","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1172\/JCI38988","volume":"119","author":"AM Santos","year":"2009","unstructured":"Santos, A. M., Jung, J., Aziz, N., Kissil, J. L. & Pur\u00e9, E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J. Clin. Invest. 119, 3613\u20133625 (2009).","journal-title":"J. Clin. Invest."},{"key":"1165_CR39","doi-asserted-by":"publisher","unstructured":"Peiffer, R. et al. Cancer-associated fibroblast diversity shapes tumor metabolism in pancreatic cancer. Cancers https:\/\/doi.org\/10.3390\/cancers15010061 (2022).","DOI":"10.3390\/cancers15010061"},{"key":"1165_CR40","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.cell.2013.03.028","volume":"153","author":"N Ding","year":"2013","unstructured":"Ding, N. et al. A vitamin D receptor\/SMAD genomic circuit gates hepatic fibrotic response. Cell 153, 601\u2013613 (2013).","journal-title":"Cell"},{"key":"1165_CR41","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.3389\/fimmu.2019.01307","volume":"10","author":"E Karkeni","year":"2019","unstructured":"Karkeni, E. et al. Vitamin D controls tumor growth and CD8+ T cell infiltration in breast cancer. Front. Immunol. 10, 1307 (2019).","journal-title":"Front. Immunol."},{"key":"1165_CR42","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41416-018-0298-0","volume":"120","author":"M Gao","year":"2019","unstructured":"Gao, M. et al. Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer. Br. J. Cancer 120, 88\u201396 (2019).","journal-title":"Br. J. Cancer"},{"key":"1165_CR43","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.ccell.2021.07.007","volume":"39","author":"WA Freed-Pastor","year":"2021","unstructured":"Freed-Pastor, W. A. et al. The CD155\/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell 39, 1342\u20131360 (2021).","journal-title":"Cancer Cell"},{"key":"1165_CR44","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(22)00369-2","volume":"23","author":"KA Reiss","year":"2022","unstructured":"Reiss, K. A. et al. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b\/2 trial. Lancet Oncol. 23, 1009\u20131020 (2022).","journal-title":"Lancet Oncol."},{"key":"1165_CR45","doi-asserted-by":"publisher","unstructured":"Loch, F. N. et al. The immune checkpoint landscape in tumor cells of pancreatic ductal adenocarcinoma. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms24032160 (2023).","DOI":"10.3390\/ijms24032160"},{"key":"1165_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36296-4","volume":"14","author":"G Werba","year":"2023","unstructured":"Werba, G. et al. Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Nat. Commun. 14, 797 (2023).","journal-title":"Nat. Commun."},{"key":"1165_CR47","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","volume":"63","author":"SM Sprague","year":"2003","unstructured":"Sprague, S. M., Llach, F., Amdahl, M., Taccetta, C. & Batlle, D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 63, 1483\u20131490 (2003).","journal-title":"Kidney Int."},{"key":"1165_CR48","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1053\/j.ajkd.2020.02.439","volume":"76","author":"SC Palmer","year":"2020","unstructured":"Palmer, S. C. et al. Comparative effectiveness of calcimimetic agents for secondary hyperparathyroidism in adults: a systematic review and network meta-analysis. Am. J. Kidney Dis. 76, 321\u2013330 (2020).","journal-title":"Am. J. Kidney Dis."},{"key":"1165_CR49","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1158\/1078-0432.CCR-23-1405","volume":"29","author":"PM Grierson","year":"2023","unstructured":"Grierson, P. M. et al. A pilot study of paricalcitol plus nanoliposomal irinotecan and 5-FU\/LV in advanced pancreatic cancer patients after progression on gemcitabine-based therapy. Clin. Cancer Res. 29, 4733\u20134739 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1165_CR50","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1002\/cncr.31676","volume":"124","author":"C Fountzilas","year":"2018","unstructured":"Fountzilas, C. et al. A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. Cancer 124, 3890\u20133899 (2018).","journal-title":"Cancer"},{"key":"1165_CR51","doi-asserted-by":"publisher","first-page":"476","DOI":"10.4161\/cbt.24350","volume":"14","author":"JA Lawrence","year":"2013","unstructured":"Lawrence, J. A., Akman, S. A., Melin, S. A., Case, L. D. & Schwartz, G. G. Oral paricalcitol (19-nor-1,25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer: a feasibility trial. Cancer Biol. Ther. 14, 476\u2013480 (2013).","journal-title":"Cancer Biol. Ther."},{"key":"1165_CR52","doi-asserted-by":"publisher","first-page":"8680","DOI":"10.1158\/1078-0432.CCR-05-1237","volume":"11","author":"GG Schwartz","year":"2005","unstructured":"Schwartz, G. G. et al. Phase I\/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin. Cancer Res. 11, 8680\u20138685 (2005).","journal-title":"Clin. Cancer Res."},{"key":"1165_CR53","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","volume":"24","author":"KL Aung","year":"2018","unstructured":"Aung, K. L. et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin. Cancer Res. 24, 1344\u20131354 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1165_CR54","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-24-0740","author":"A Singhal","year":"2024","unstructured":"Singhal, A. et al. A classical epithelial state drives acute resistance to KRAS inhibition in pancreas cancer. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.Cd-24-0740 (2024).","journal-title":"Cancer Discov."},{"key":"1165_CR55","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-24-0177","author":"J Dilly","year":"2024","unstructured":"Dilly, J. et al. Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.Cd-24-0177 (2024).","journal-title":"Cancer Discov."},{"key":"1165_CR56","doi-asserted-by":"publisher","first-page":"e081123","DOI":"10.1136\/bmj-2024-081123","volume":"389","author":"S Hopewell","year":"2025","unstructured":"Hopewell, S. et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. Brit. Med. J. 389, e081123 (2025).","journal-title":"Brit. Med. J."},{"key":"1165_CR57","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1053\/j.jrn.2016.02.006","volume":"26","author":"J Kumar","year":"2016","unstructured":"Kumar, J. et al. Successful conversion from parenteral paricalcitol to pulse oral calcitriol for the management of secondary hyperparathyroidism in hemodialysis patients. J. Ren. Nutr. 26, 265\u2013269 (2016).","journal-title":"J. Ren. Nutr."},{"key":"1165_CR58","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2215\/CJN.07960719","volume":"15","author":"RI Thadhani","year":"2020","unstructured":"Thadhani, R. I. et al. Conversion from intravenous vitamin D analogs to oral calcitriol in patients receiving maintenance hemodialysis. Clin. J. Am. Soc. Nephrol. 15, 384\u2013391 (2020).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1165_CR59","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"1165_CR60","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/1078-0432.CCR-20-3141","volume":"27","author":"SA V\u00e4yrynen","year":"2021","unstructured":"V\u00e4yrynen, S. A. et al. Composition, spatial characteristics, and prognostic significance of myeloid cell infiltration in pancreatic cancer. Clin. Cancer Res. 27, 1069\u20131081 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1165_CR61","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinf. 14, 7 (2013).","journal-title":"BMC Bioinf."},{"key":"1165_CR62","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.molcel.2010.05.004","volume":"38","author":"S Heinz","year":"2010","unstructured":"Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576\u2013589 (2010).","journal-title":"Mol. Cell"},{"key":"1165_CR63","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"1165_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"MM Bates D","year":"2015","unstructured":"Bates D, M. M., Bolker, B. & Walker, S. Fitting linear mixed-effects models using lme4. J. Stat. Softw. 67, 1\u201348 (2015).","journal-title":"J. Stat. Softw."},{"key":"1165_CR65","doi-asserted-by":"publisher","unstructured":"Perez, K. J. et al. Multiplexed tissue immunofluorescence data from a clinical trial of gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer. Zenodo https:\/\/doi.org\/10.5281\/zenodo.17969216 (2025).","DOI":"10.5281\/zenodo.17969216"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01165-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01165-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01165-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:04:13Z","timestamp":1782482653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01165-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":65,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["1165"],"URL":"https:\/\/doi.org\/10.1038\/s43018-026-01165-8","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"1 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: K.J.P.: The authors held a one-time advisory role for Ipsen, Exelixis and Novartis. J.M.C.: The author receives research funding to his institution from Amgen, Merus, Servier and Bristol Myers Squibb. He receives research support from Merck, AstraZeneca, Esperas Pharma, Bayer, Tesaro, Arcus Biosciences and Pyxis; he has also received honoraria for being on the advisory boards of Incyte and Blueprint Medicines and for serving on the data safety monitoring committee for AstraZeneca. He has given educational talks sponsored by Bayer, Bristol Myers Squibb, Lilly, Merck, AstraZeneca and Genentech. A.E.: The author receives research funding from Medtronic, Inc. Spouse has been a consultant for and has received honoraria from ALX oncology, Arcus Bioscience, Astellas, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Chimeric Therapeutics, Celgene, Coherus, Daiichi-Sankyo, Five Prime, Ideaya, Istari, Legend, Lily, Loxo, Merck, Novartis, Ono, Servier, Taiho, Takeda, Turning Point Therapeutics, Xencor and Zymeworks. D.A.R.: The author receives research funding Instylla, Boston Scientific, Axial Therapeutics, Taiho, Sirtex. H.S.: The author receives research funding from AstraZeneca, has consulted for Dewpoint Therapeutics, Inc. and Merck Sharp & Dohme, LLC. Travel and accommodation from Dava Oncology. Honoraria from UpToDate. T.A.: The author receives research funding to his institution from Lilly, Sanofi; receives consulting fees from Eisai and AstraZeneca; stock ownership in Merck. P.S.W.: Receives research support from Microsoft and reports compensation for consulting from The Engine Ventures unrelated to this work. S.R.: Research support from Microsoft, equity in Amgen. T.B.K.: Research support to institution from AstraZeneca, Eli Lilly, Tempest Therapeutics, Xencor, Genentech, Totus Medicines, Boehringer Ingelheim, Replimune, BioNTech, PMV Pharma and Frontier Medicines. Consulting\/advisory boards for Pfizer, Merus, Incyte, Nucorion Pharmaceuticals and Synnovation Therapeutics. P.O.D.: Research Support: Pfizer, BMS, AZ, GSK, Five Prime, Merck, Syndax, BBI, Novartis, Celgene, Incyte, Lilly\/Imclone, array, h3biomedicine, Taiho, Minneamrata, pharmacyclics\/abbvie, Mirati. J.A.N.: The author receives research funding from Natera and serves as a consultant for Leica Biosystems. B.M.W.: Research funding to institution: Amgen, AstraZeneca, BMS\/Celgene, BreakThrough Cancer, Eli Lilly, Harbinger Health, Lustgarten Foundation, NIH\/NCI, Novartis, Pancreatic Cancer Action Network, Revolution Medicines, Servier\/Agios, Stand Up to Cancer. Advisory boards\/consulting: Agenus, BMS\/Mirati, EcoR1 Capital, GRAIL, Harbinger Health, Ipsen, Lustgarten Foundation, Revolution Medicines, Tango Therapeutics, Third Rock Ventures. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}